ESMO 2024 | Phase I/II trial of CFT1946 in mutant BRAF V600 tumors

Maria Vieito • 16 Sep 2024

ESMO 2024

General CFT1946

Maria Vieito, MD, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discusses early findings from the Phase I/II trial (NCT05668585) of CFT1946, an oral BiDAC™ degrader targeting BRAF V600 mutant proteins. Early results show promising tumor response, BRAF V600 degradation, and pathway inhibition, even in heavily-pretreated patients. A favorable safety profile was additionally reported and ongoing dose exploration is underway. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.